ArticleEndocrine connections2026
Myopathy in endogenous Cushing's syndrome: type II muscle fiber atrophy and its association with age and circulating IGF-1.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextPatients with endogenous Cushing's syndrome (CS) exhibit reduced muscle strength compared with healthy individuals and frequently experience a further postoperative decline despite remission.
objectiveTo evaluate the histological and immunohistochemical patterns underlying myopathy in patients with active and remitted CS. PATIENTS AND
methodsWe included nine patients with active CS and eight patients with CS in remission, prospectively enrolled at LMU Hospital. Patients in remission had curative tumor surgery and biochemical remission for ≥24 months. Biopsies of the vastus lateralis muscle were obtained surgically and analyzed by histology, immunohistochemistry and electron microscopy. IGF-1 concentrations were determined using an IDS-iSYS analyzer.
resultsIn active CS, the mean cross-sectional area of type II muscle fibers was reduced. Nicotinamide adenine dinucleotide staining revealed mild moth-eaten fiber patterns in four patients, accompanied by ultrastructural pathologies on electron microscopy, including increased subsarcolemmal mitochondrial aggregates that were also present in remitted CS. In active CS, circulating absolute IGF-1 concentrations positively (rs = 0.8, P = 0.014) and age inversely (rs = -0.77, P = 0.021) correlated with mean cross-sectional area of type II muscle fibers. In remission from CS, type II fiber atrophy was not present in most patients. No substantial associations were found between the severity of glucocorticoid excess and histological alterations during active or remitted disease.
conclusionActive CS is characterized by type II fiber atrophy and is associated with circulating IGF-1 and age. In remission, type II fiber atrophy was not present, whereas mitochondrial ultrastructural alterations could be observed. These findings indicate sustained muscle alterations and highlight the need for mechanistic studies to guide targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.